Mutation Update
Full Access
CDKN2A (p16INK4A) somatic and germline mutations
Birgitte Smith-Sørensen,
Eivind Hovig,
Birgitte Smith-Sørensen
Departments of Genetics and Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo Norway
Search for more papers by this authorCorresponding Author
Eivind Hovig
Departments of Genetics and Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo Norway
Departments of Genetics and Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo Norway; Fax: 47-225 22421Search for more papers by this authorBirgitte Smith-Sørensen,
Eivind Hovig,
Birgitte Smith-Sørensen
Departments of Genetics and Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo Norway
Search for more papers by this authorCorresponding Author
Eivind Hovig
Departments of Genetics and Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo Norway
Departments of Genetics and Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo Norway; Fax: 47-225 22421Search for more papers by this authorFirst published: 1996
Citations: 60
Abstract
The cell cycle is composed of a series of steps that can be negatively or positively regulated by various factors. A group of low-molecular-weight proteins have recently been identified that specifically inhibit the function of cyclin-dependent kinases in mammalian cells. Inactivation of the CDKN2A gene (also known as p16INK4A and MTS1) attracted considerable interest after it was mapped to 9p21, a locus for familial melanoma. In an effort to standardize the information regarding human CDKN2A mutations detected in cancers, a database with information of 146 point mutations has been created. Cancer type, origin of cells, specific mutation, amino acid change, literature citation, and other data are provided for each mutation entry. Studies of biochemical and biological functions of both wild-type and mutant proteins are central to our understanding of the role of p16INK4a mutations in tumorigenesis, a summary of these studies is also included in the present update. © 1996 Wiley-Liss, Inc.
References
- Berns E, Klijn J, Smid M, Van SI, Gruis NA, Foekens JA (1995) Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer 72: 964–967.
- Blanquet V, Turleau C, Gross-Morand MS, Senamaud-Beaufort C, Doz F, Besmond C (1995) Spectrum of germline mutations in the RB1 gene: A study of 232 patients with hereditary and non hereditary retinoblastoma. Hum Mol Genet 4: 383–388.
- Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88: 10124–10128.
- Brenner AJ, Aldaz CM (1995) Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Research 55: 2892–2895.
- Cairns P, Shaw ME, Knowles MA, Grana X, Reddy EP (1993) Initiation of bladder cancer may involve deletion of a tumoursuppressor gene on chromosome 9. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 8: 1083–1085.
- Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE, Sidransky D (1994a) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265: 415–417.
- Cairns P, Tokino K, Eby Y, Sidransky D (1994b) Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 54: 1422–1424.
- Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8: 27–32.
- Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, Hegi ME, Wiseman RW, Petty EM, Bale AE et al. (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 258: 1148–1152.
- Cannon-Albright LA, Goldgar DE, Neuhausen S, Gruis NA, Anderson DE, Lewis CM, Jost M, Tran TD, Nyguen K, Kamb A et al. (1994) Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics 23: 265–268.
- Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR (1994) p16 alterations and deletion mapping of 9p21vp22 in malignant mesothelioma. Cancer Res 54: 5547–5551.
- Dei Tos AP, Maestro R, Doglioni C, Gasparotto D, Boiocchi M, Laurino L, Fletcher CD (1994) Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol 145: 11–17.
- Gonzalez-Zulueta M, Shibata A, Ohneseit PF, Spruck ChIH, Busch C, Shamaa M, Elbaz M, Nichols PW, Gonzalgo ML, Malmström P-U, Jones PA (1995) High frequency of chromosome 9p allelic loss and CDKN2 tumor supprossor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst 87: 1383–1393.
- Grana X, Reddy EP (1995) Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211–219.
- Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castaneda V, Lianes P, Latres E, Skolnick M, Cordon-Cardo C, Kamb A (1995a) Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 146: 1199–1206.
- Gruis NA, Van der Velden PA, Sandkuij LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR (1995b) Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 10: 351–353.
- Haidar MA, Cao XB, Manshouri T, Chan LL, Glassman A, Kantarjian HM, Keating MJ, Beran MS, Albitar M (1995) p16INK4A and p15INK4B gene deletions in primary leukemias. Blood 86: 311–315.
- Hall M, Bates S, Peters G (1995) Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11: 1581–1588.
- Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371: 257–261.
- Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318–1327.
- Hayashi N, Sugimota Y, Tsuchiya E, Ogawa M, Nakamura Y (1994) Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 202: 1426–1430.
- He J, Allen JR, Collins VP, Allalunis TM, Godbout R, Day RR, James CD (1994) CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54: 5804–5807.
- Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22: 3551–3555.
- Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nature Genet 8: 15–21.
- Igaki H, Sasaki H, Tachimori Y, Kato H, Watanabe H, Kimura T, Harada Y, Sugimura T, Terada M (1995) Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 55: 3421–3423.
- Kai M, Arakawa H, Sugimoto Y, Murata Y, Ogawa M, Nakamura Y (1995) Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas. Jpn J Cancer Res 86: 249–251.
- Kamb A (1995) Cell-cycle regulators and cancer. Trends Genet 11: 136–140.
- Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH (1994a) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436–440.
- Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J (1994b) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8: 23–26.
- Koh J, Enders GH, Dynlacht BD, Harlow E (1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506–510.
- Komiya A, Suzuku H, Aida S, Yatani R, Shimazaki J (1995) Mutational analysis of CDKN2 (CDK4/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 86: 622–625.
- Li Y, Nichols MA, Shay JW, Xiong Y (1994) Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54: 6078–6082.
- Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R (1995) Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11: 597–600.
- Liu Q, Yan YX, McClure M, Nakagawa H, Fujimura F, Rustgi AK (1995a) MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene 10: 619–622.
- Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A (1995b) CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10: 1061–1067.
- Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, Hogg D (1995c) Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11: 405–412.
- Lo KW, Huang DP, Lau KM (1995) p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 55: 2039–2043.
- Luca M, Xie SH, Gutman M, Huang SY, Bar EM (1995) Abnormalities in the CDKN2 (p16INK4/MTS1) gene in human melanoma cells: Relevance to tumor growth and metastasis. Oncogene 11: 1399–1402.
- Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503–506.
- Maelandsmo GM, Berner JM, Florenes VA, Forus A, Hovig E, Fodstad O, Myklebost O (1995) Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas—relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 72: 393–398.
- Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D (1995) A novel p16INK4A transcript. Cancer Res 55: 2995–2997.
- Merlo A, Gabrielson E, Askin F, Sidransky D (1994a) Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res 54: 640–642.
- Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin SB, Sidransky D (1994b) Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res 54: 2322–2326.
- Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1: 686–692.
- Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y (1994) Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54: 3396–3397.
- Moulton T, Samara G, Chung WY, Yuan L, Desai R, Sisti M, Bruce J, Tycko B (1995) MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 146: 613–619.
- Nakamaki T, Kawamata N, Schwaller J, Tobler A, Fey M, Pakkala S, Lee YY, Kim BK, Fukuchi K, Tsuruoka N, Kahan J (1995) Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Br J Haematol 91: 139–149.
- Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM, Sidransky D (1994) Allelotype of head and neck squamous cell carcinoma. Cancer Res 54: 1152–1155.
- Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753–756.
- Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S, Hayashi Y (1995) Homozygous deletions of p16/MTSI gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 86: 1269–1275.
- Ohta M, Nagai H, Shimizu M, Rasio D, Berd D. Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, et al. (1994) Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 54: 5269–5272.
- Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC (1994) Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045–11049.
- Okamoto A, Hussain SP, Hagiwara K, Spillare EA, Rusin MR, Demetrick DJ, Serrano M, Hannon GJ, Shiseki M, Zariwala M, Xiong Y, Beach DH, Yokota J, Harris CC (1995) Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55: 1448–1451.
- Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M (1995) Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55: 1436–1440.
- Pollock PM, Yu F, Qui L, Parsons PG, Hayward NK (1995) Evidence for uv induction of CDKN2 mutations in melanoma cell lines. Oncogene 11: 663–668.
- Quesnel B, Fenaux P, Philippe N, Fournier J, Bonneterre J. Preudhomme C, Peyrat JP (1995b) Analysis of p16 gene deletion and point mutation in breast carcinoma. Br J Cancer 72: 351–353.
- Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Lai JL, Bauters F, Wattel E, Fenaux P (1995a) p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 85: 657–663.
- Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC (1995) Mutations associated with familial melanoma impair p16INK4 function. Nature Genet 10: 114–116.
- Rasool O, Heyman M, Borgonovo Brandter L, Liu Y, Grander D, Söderhäll S, Einhorn S (1995) p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia. Blood 85: 3431–3436.
- Reymond A, Brent R (1995) p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 11: 1173–1178.
- Sakata K, Tamura G, Maesawa C, Suzuki Y, Terashima M, Satoh K, Eda Y, Suzuki A, Sekiyama S, Satodate R (1995) Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas. Jpn J Cancer Res 86: 333–335.
- Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK (1995) Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 55: 2150–2157.
- Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D (1995) Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 267: 249–252.
- Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–707.
- Spruck CH, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA (1994) p16 gene in uncultured tumours. Nature 370: 183–184.
- Stone S, Dayananth P, Jiang P, Weaver-Feldhaus JM, Tavtigian SV, Cannon-Albright L, Kamb A (1995a) Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 11: 987–991.
- Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A<;/a> (1995b) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55: 2988–2994.
- Ueki K, Rubio MP, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN (1994) MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 3: 1841–1845.
- Walker GJ, Hussussian CJ, Floré JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW (1995) Mutations of the CDKN2/p161NK4 gene in Australian melanoma kindreds. Hum Mol Genet 4: 1845–1852.
- Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T, Takahashi T (1995) In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in nonsmall cell lung cancers. Cancer Res 55: 514–517.
- Whelan AJ, Bartsch D, Goodfellow PJ (1995) A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333: 975–977.
- Whitaker NJ, Bryan TM, Bonnefin P, Chang AC, Musgrove EA, Braithwaite AW, Reddel RR (1995) Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. Oncogene 11: 971–976.
- Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA (1995) p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569–1577.
- Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Büohenfelde, K-HM, Beach D (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281–1284.
- Xiao S, Li D, Corson JM, Vijg J, Fletcher JA (1995) Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 55: 2968–2971.
- Yandell DW, Campbell TA, Dayton SH, Petersen R, Walton D, Little JB, McConkie-Rosell A, Buckley EG, Dryja TP (1989) Oncogenic point mutations in the human retinoblastoma gene: Their application to genetic counseling. N Engl J Med 321: 1689–1695.
- Yang R, Gombart AF, Serrano M, Koeffler HP (1995) Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res 55: 2503–2506.
- Yeudall WA, Crawford RY, Ensley JF, Robbins KC (1994) MTS1/CDK41 is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 15: 2683–2686.
- Yoshida S, Todoroki T, Ichikawa Y, Hanai S, Suzuki H, Hori M, Fukao K, Miwa M, Uchida K (1995) Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 55: 2756–2760.
- Zhang SY, Klein-Szanto AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL (1994) Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54: 5050–5053.
- Zhou X, Tarmin L, Yin J, Jiang HY, Suzuki H, Rhyu MG, Abraham JM, Meltzer SJ (1994) The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9: 3737–3741.
